Challenges and opportunities for medications development in alcoholism: An international perspective on collaborations between academia and industry
(2005) In Alcoholism: Clinical and Experimental Research 29(8). p.1528-1540- Abstract
- This article represents the proceedings of a symposium presented at the 12th Congress of the International Society for Biomedical Research on Alcoholism held in Heidelberg/Mannheim, Germany, on September 30, 2004. The organizers and cochairs were Bankole A. Johnson, DSc, MD, PhD, and Karl Mann, MD. The presentations included the following: (1) A Perspective from Academia, by Bankole A. Johnson, DSc, MD, PhD; (2) A Perspective from NIAAA, by Mark L. Willenbring, MD; (3) A Perspective from US Clinical Practice, by Robert M. Swift, MD, PhD; (4) A European Perspective on Medications Development, by Otto M. Lesch, MD, PhD, and (5) A Scandinavian Perspective on Evidence-Based Addiction Treatment, by Mats Berglund, MD.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/225115
- author
- Johnson, B A ; Mann, K ; Willenbring, M L ; Litten, R Z ; Swift, R M ; Lesch, O M and Berglund, Mats LU
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- antagonist, cannabinoid, acamprosate, naltrexone, ondansetron, alcohol, topiramate
- in
- Alcoholism: Clinical and Experimental Research
- volume
- 29
- issue
- 8
- pages
- 1528 - 1540
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000231767900021
- pmid:16156050
- scopus:24144470778
- ISSN
- 0145-6008
- DOI
- 10.1097/01.alc.0000174690.63787.fc
- language
- English
- LU publication?
- yes
- id
- 317c4acc-e7cc-4d26-9848-bd0f103d83e1 (old id 225115)
- date added to LUP
- 2016-04-01 12:17:07
- date last changed
- 2022-01-27 01:28:36
@article{317c4acc-e7cc-4d26-9848-bd0f103d83e1, abstract = {{This article represents the proceedings of a symposium presented at the 12th Congress of the International Society for Biomedical Research on Alcoholism held in Heidelberg/Mannheim, Germany, on September 30, 2004. The organizers and cochairs were Bankole A. Johnson, DSc, MD, PhD, and Karl Mann, MD. The presentations included the following: (1) A Perspective from Academia, by Bankole A. Johnson, DSc, MD, PhD; (2) A Perspective from NIAAA, by Mark L. Willenbring, MD; (3) A Perspective from US Clinical Practice, by Robert M. Swift, MD, PhD; (4) A European Perspective on Medications Development, by Otto M. Lesch, MD, PhD, and (5) A Scandinavian Perspective on Evidence-Based Addiction Treatment, by Mats Berglund, MD.}}, author = {{Johnson, B A and Mann, K and Willenbring, M L and Litten, R Z and Swift, R M and Lesch, O M and Berglund, Mats}}, issn = {{0145-6008}}, keywords = {{antagonist; cannabinoid; acamprosate; naltrexone; ondansetron; alcohol; topiramate}}, language = {{eng}}, number = {{8}}, pages = {{1528--1540}}, publisher = {{Wiley-Blackwell}}, series = {{Alcoholism: Clinical and Experimental Research}}, title = {{Challenges and opportunities for medications development in alcoholism: An international perspective on collaborations between academia and industry}}, url = {{http://dx.doi.org/10.1097/01.alc.0000174690.63787.fc}}, doi = {{10.1097/01.alc.0000174690.63787.fc}}, volume = {{29}}, year = {{2005}}, }